Unintended consequences of decreased PSA-based prostate cancer screening

被引:32
作者
Ahlering, Thomas [1 ]
Huynh, Linda My [1 ]
Kaler, Kamaljot S. [1 ]
Williams, Stephen [2 ]
Osann, Kathryn [3 ]
Joseph, Jean [4 ]
Lee, David [5 ]
Davis, John W. [6 ]
Abaza, Ronney [7 ]
Kaouk, Jihad [8 ]
Patel, Vipul [9 ]
Kim, Isaac Yi [10 ]
Porter, James [11 ]
Hu, Jim C. [12 ]
机构
[1] Univ Calif Irvine Hlth, Dept Urol, 333 City Blvd West,Suite 2100, Orange, CA 92868 USA
[2] Univ Texas Med Branch, Dept Surg, Div Urol, Galveston, TX 77555 USA
[3] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA
[4] Univ Rochester, Dept Urol, Rochester, NY USA
[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Ohio Hlth Robot Urol Surg, Dept Urol, Dublin, OH USA
[8] Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA
[9] Florida Celebrat Hlth, Dept Urol, Kissimmee, FL USA
[10] Rutgers Canc Ctr New Jersey, Dept Urol, New Brunswick, NJ USA
[11] Swedish Med Ctr, Dept Urol, Seattle, WA USA
[12] Weill Cornell Med, New York, NY USA
关键词
Prostate cancer; Screening; USPSTF recommendation; High risk; UNITED-STATES; NATURAL-HISTORY; RISK; ANTIGEN; BENEFITS; TRENDS; MEN;
D O I
10.1007/s00345-018-2407-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In May 2012, the US Preventive Services Task Force issued a grade D recommendation against PSA-based prostate cancer screening. Epidemiologists have concerns that an unintended consequence is a problematic increase in high-risk disease and subsequent prostate cancer-specific mortality. To assess the effect of decreased PSA screening on the presentation of high-risk prostate cancer post-radical prostatectomy (RP). Nine high-volume referral centers throughout the United States (n = 19,602) from October 2008 through September 2016 were assessed and absolute number of men presenting with GS ae8, seminal vesicle and lymph node invasion were compared with propensity score matching. Compared to the 4-year average pre-(Oct. 2008-Sept. 2012) versus post-(Oct. 2012-Sept. 2016) recommendation, a 22.6% reduction in surgical volume and increases in median PSA (5.1-5.8 ng/mL) and mean age (60.8-62.0 years) were observed. The proportion of low-grade GS 3 + 3 cancers decreased significantly (30.2-17.1%) while high-grade GS 8 + cancers increased (8.4-13.5%). There was a 24% increase in absolute numbers of GS 8+ cancers. One-year biochemical recurrence rose from 6.2 to 17.5%. To discern whether increases in high-risk disease were due to referral patterns, propensity score matching was performed. Forest plots of odds ratios adjusted for age and PSA showed significant increases in pathologic stage, grade, and lymph node involvement. All centers experienced consistent decreases of low-grade disease and absolute increases in intermediate and high-risk cancer. For any given age and PSA, propensity matching demonstrates more aggressive disease in the post-recommendation era.
引用
收藏
页码:489 / 496
页数:8
相关论文
共 35 条
  • [31] Further Evidence That Prostate-Specific Antigen Screening Reduces Prostate Cancer Mortality
    Stampfer, Meir J.
    Jahn, Jaquelyn L.
    Gann, Peter H.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (03):
  • [32] Tanimoto R, 2017, BMC UROL, V35, DOI [10.1016/j.urolonc.2016.10.015, DOI 10.1016/J.UROLONC.2016.10.015]
  • [33] Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
    Tsodikov, Alex
    Gulati, Roman
    Heijnsdijk, Eveline A. M.
    Pinsky, Paul F.
    Moss, Sue M.
    Qiu, Sheng
    de Carvalho, Tiago M.
    Hugosson, Jonas
    Berg, Christine D.
    Auvinen, Anssi
    Andriole, Gerald L.
    Roobol, Monique J.
    Crawford, E. David
    Nelen, Vera
    Kwiatkowski, Maciej
    Zappa, Marco
    Lujan, Marcos
    Villers, Arnauld
    Feuer, Eric J.
    de Koning, Harry J.
    Mariotto, Angela B.
    Etzioni, Ruth
    [J]. ANNALS OF INTERNAL MEDICINE, 2017, 167 (07) : 449 - +
  • [34] Screening for prostate cancer: US preventive services task force recommendation statement
    Calonge N.
    Petitti D.B.
    Dewitt T.G.
    Dietrich A.J.
    Gregory K.D.
    Harris R.
    Isham G.J.
    Lefevre M.L.
    Leipzig R.
    Loveland-Cherry C.
    Marion L.N.
    Melnyk B.
    Moyer V.A.
    Ockene J.K.
    Sawaya G.F.
    Yawn B.P.
    [J]. ANNALS OF INTERNAL MEDICINE, 2008, 149 (03) : 185 - 191
  • [35] Utilization and Expense of Adjuvant Cancer Therapies Following Radical Prostatectomy
    Williams, Stephen B.
    Gu, Xiangmei
    Lipsitz, Stuart R.
    Nguyen, Paul L.
    Choueiri, Toni K.
    Hu, Jim C.
    [J]. CANCER, 2011, 117 (21) : 4846 - 4854